Publications
Below is a collection of independent, peer-reviewed publications providing evidence for the role of AXL biology in driving immune suppression and tumor immune evasion as well as therapy resistance and cancer spread.
Scientific publications
ASCO 2022, Bhalla et al.
Phase 1 dose escalation and expansion study of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced NSCLC
ASH 2021, Sonja Loges et al.
13th December 2021
Bemcentinib (Oral AXL Inhibitor) in combination with Low-dose Cytarabine Is Well Tolerated and Efficacious in Older Relapsed AML Patients. Updates from the Ongoing Phase II Trial (NCT02488408) and Preliminary Translational Results indicating Bemcentinib elicits anti-AML immune responses.
SITC 2021, Rolf A. Brekken et al.
9th November 2021
AXL targeting with bemcentinib restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through innate immune cell mediated expansion of TCF1+ CD8 T cells
ASV 2021, Mr. Dana Bohan
20th July 2021
Phosphatidylserine Receptors Enhance SARS-CoV-2 Infection: AXL as a Therapeutic Agent for COVID-19
Non-Small Cell Lung Cancer Drug Development Summit 2021, Prof. Hani Gabra
15th July 2021
Reprogramming of the Lung Cancer Tumor Microenvironment With the AXL Inhibitor Bemcentinib
ECCMID 2021, Akil Jackson
12th July 2021
Bemcentinib, an oral AXL kinase inhibitor, results in lower mortality compared to standard of care (steroids with or without remdesivir) in hospitalised patients with COVID-19
EAU 2021, Tony J. Chen
10th July 2021
Successful therapy of experimental, orthotopic renal cell carcinoma with two different types of AXL-inhibiting agents
4th Annual Next Gen Immuno-Oncology Congress, Prof. Hani Gabra
1st July 2021
The role of AXL in immuno-oncology: A translational perspective
EHA 2021, Dr. Sonja Loges et al.
11 June 2021
The combination of AXL inhibitor bemcentinib and low-dose cytarabine is well tolerated and efficacious in elderly relapsed AML patients: Update from the ongoing BGBC003 Phase II trial (NCT02488408)
ERA-EDTA 2021, Linn Hodneland Nilsson
6 June 2021
Tilvestamab, a function-blocking monoclonal antibody inhibitor of AXL RTK signalling, limits the onset of renal fibrotic changes in human kidneys ex vivo
ASCO 2021, Lauren Byers et al.
4 June 2021
Ph I/II study of oral selective AXL inhibitor bemcentinib (BGB324) in combination with erlotinib in patients with EGFRm NSCLC: End of trial update
Virtual Immunology 2021, Dana Bohan et al.
10 May 2021
Phosphatidylserine Receptors Enhancement of SARS-CoV-2 Entry: AXL as a Therapeutic Target for COVID-19
CROI 2021, Wendy Maury et al.
6 March 2021
Targeting of the Receptor Tyrosine Kinase AXL by Bemcentinib prevents SARS-CoV-2 infection
ASH 2020, Prof. Sonja Loges et al.
6 December 2020
The combination of AXL inhibitor bemcentinib and low dose cytarabine is well tolerated and efficacious in elderly relapsed AML patients: an update from the ongoing BGBC003 Phase II Trial
ASH 2020, Prof. Uwe Platzbecker et al.
5 December 2020
Efficacy and safety of bemcentinib in patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia failing Hypomethylating Agents
SITC 2020, Professor James Spicer, PhD, FRCP
11 November 2020
A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab, in pts with previouslytreated advanced NSCLC: Updated clinical & translational analysis
ASH 2019, Sonja Loges et al
9 December 2019, Orlando, USA
Durable responses observed in elderly AML patients ufit for intencive chemotherapy with First-in-Class selective AXL inhibitor bemcentinib (BGB324) in combination with LDAC: Phase II open-label study.
SITC 2019, Matthew Krebs et al
8 November 2019, Maryland, USA
Oral presentation in High Impact Clinical Trials:
A phase II study of bemcentinib (BGB324), a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced NSCLC: Updated analysis
ESMO 2019, Oddbjørn Straume et al
30 September 2019, Barcelona, Spain
Poster Presentation:
Trial update: A randomized Phase Ib/II study of the selective small molecule Axl inhibitor bemcentinib (BGB324) in combination with either dabrafenib/trametinib (D/T) or pembrolizumab in patients with metastatic melanoma
ESMO 2019, Jose M. Trigo Perez et al
28 September 2019, Barcelona, Spain
Poster Presentation:
Preliminary efficacy results of selective AXL inhibitor bemcentinib with pembrolizumab following chemo in patients with NSCLC
CICON 2019, Kjersti T. Davidsen et al
27 September 2019, Paris, France
Poster presentation:
AXL Inhibition Improves Immunotherapy by Targeting Local and Systemic Tumor Myeloid Cross-Talk
WCLC 2019, Felip et al
07 – 10 September 2019, Barcelona, Spain
Mini-oral Presentation:
Efficacy Results of Selective AXL Inhibitor Bemcentinib with Pembrolizumab Following Chemotherapy in Patients with NSCLC
WCLC 2019, Krebs et al
07 – 10 September 2019, Barcelona, Spain
Poster Presentation:
A Phase II Study of Selective AXL Inhibitor Bemcentinib and Pembrolizumab in Patients with NSCLC Refractory to Anti-PD(L)1
EHA 24, Hellesøy et al
June 13 - 16 2019, Amsterdam, Netherlands
Poster Presentation:
Single Cell Signaling Pharmacodynamics in a Phase 1b Clinical Trial of the AXL inhibitor bemcentinib in Acute Myeloid Leukemia and Myelodysplastic Syndrome
EHA 24, Loges at al
June 13 - 16 2019, Amsterdam, Netherlands
Poster Presentation:
The Combination of bemcentinib, a novel, oral, selective AXL-Inhibitor and Low-Dose Cytarabine yields Durable Responses in AML patients Unfit for Intensive Chemotherapy
ASCO 2019, Loges et al
May 31 - Jun 4 2018: Chicago, IL
Poster Presentation:
First-in-class selective AXL inhibitor bemcentinib (BGB324) in combination with LDAC or decitabine exerts anti-leukaemic activity in AML patients unfit for intensive chemotherapy: a Phase II open-label study
ASCO 2019, Felip et al
May 31 - Jun 4 2018: Chicago, IL
Poster Presentation:
A phase II study of bemcentinib (BGB324), a first-in-class highly selective AXL inhibitor, with pembrolizumab in patients with advanced NSCLC: OS for stage I and preliminary stage II efficacy.
CCBIO, Blø et al
May 13 - 14, 2019: Bergen, Norway
Poster Presentation:
BGB149, a novel clinical stage humanised anti-AXL function blocking antibody
AACR, Ramkumar et al
Mar 29 - Apr 3, 2019: Atlanta, Georgia
Poster presentation:
Targeting AXL sensitizes non-small cell lung cancer to ATR inhibitors by enhancing replication stress
AACR, Chouaib et al
Mar 29 - Apr 3, 2019: Atlanta, Georgia
Poster presentation:
AXL targeting enhances lymphocyte-mediated cytotoxicity of lung cancer cells
AACR, Du et al
Mar 29 - Apr 3, 2019: Atlanta, Georgia
Poster presentation:
AXL is critical for pancreatic cancer progression and metastasis
60th American Society of Hematology Meeting (ASH)
Dec 1 - 4 2018: San Diego
Poster presentation by Loges et al:
Comprehensive Analysis of the Dose Escalation, Expansion and Correlates in the Ph I/II Trial BGBC003 with the Selective Oral AXL Inhibitor Bemcentinib (BGB324) in Relapsed/Refractory AML and MDS
SITC, Krebs et al
Nov 7 - 11 2018: Washington DC
Late breaking abstract poster presentation:
A Phase II study of bemcentinib (BGB324), a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced NSCLC: Analysis of the first stage
SITC, Holt et al
Nov 7 - 11 2018: Washington DC
Poster presentation: Predictive and pharmacodynamic biomarkers associated with treatment with the oral selective AXL Inhibitor bemcentinib in combination with pembrolizumab in patients with advanced NSCLC and Melanoma
ESMO, Holt et al
Oct 19 - 23 2018: Munich, Germany
Poster Discussion: Predictive and Pharmacodynamic Biomarkers Associated with Phase II, selective and orally bioavailable AXL Inhibitor Bemcentinib Across Multiple Clinical Trials
ESMO, Schuster et al
Oct 19 - 23 2018: Munich, Germany
Poster Presentation: Update on the randomised Phase Ib/II study of the selective small molecule AXL inhibitor bemcentinib (BGB324) in combination with either dabrafenib/trametinib or pembrolizumab in patients with metastatic melanoma
ESMO, Medyouf et al
Oct 19 - 23 2018: Munich, Germany
Poster Discussion: The identification of the AXL/Gas6 signalling axis as a key player of myelodysplastic syndrome (MDS) and the potential of the oral selective AXL inhibitor bemcentinib in the treatment of MDS
23rd Congress of the European Hematology Association (EHA)
Jun 14 - 17 2018, Stockholm, Sweden
Poster presentation by Loges et al.
BerGenBio ASCO 2018 reception
The reception, which coincided with the annual American Society of Clinical Oncology (ASCO) meeting, provided stakeholders, including clinicians, investors, analysts and media, with interim data from the ongoing clinical trials of bemcentinib alone and in combination with standard of care drugs in multiple cancer indications. Presentations were made by key opinion leaders, clinical trial principle investigators and members of the BerGenBio team.